Salman Ali, who quit school to sing, emerges Indian Idol 10 winner

Bengaluru, May 29: Karnataka reported 248 new cases of coronavirus on Friday, and with that, the state tally surged to 2,781. 

A 50-year-old woman, resident of Chikkaballapura district, succumbed to the infection on Friday. She was admitted to a private hospital on May 24 following acute kidney injury and pneumonia. As her condition deterorted, she was shifted to a designated hospital in Bengaluru Urban on May 28, where she tested COVID-19 positive.

Out of the 248 cases, only 16 persons have contracted the virus inside the state. The remaining are the people who have returned from Maharashtra, Delhi, Andhra Pradesh, Tamil Nadu and Ireland.

The maximum number of people, who tested positive for COVID-19, have returned from Maharashtra. Most of these people are residents of Udupi, Kalaburagi, Yadagiri and Raichuru.

Besides, five people have a travel history to Delhi, while one person each has tested positive on returning from Andhra Pradesh, Tamil Nadu, Rajasthan and Ireland.

Fifteen people have tested positive within the state and have been infected by persons who had previously tested positive or have a history of Influenza-like Illness and Severe Acute Respiratory Illness.

Out of all the cases, 10 have been reported in Bengaluru Urban while one has come up in Bengaluru Rural.

Meanwhile, on Thursday, the Karnataka government asked the Civil Aviation Ministry to reduce the number of flights coming in the state from the five worst-hit states -- Maharashtra, Tamil Nadu, Gujarat, Madhya Pradesh and Rajasthan.

"Karnataka has appealed to the Civil Aviation Ministry to take steps to lessen the air traffic to the state, with the sacred intention that there may not be adequate quarantine facilities if there is a huge turnout in a short span of time," state Law and Parliamentary Affairs Minister J.C. Madhuswamy explained.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

In a shocking incident, a pharmacist-cum-production manager of an Ayurvedic product company in Chennai’s T.Nagar died after drinking a chemical preparation he reportedly formulated for tackling the Coronavirus.

The managing director of the company, who is an ophthamologist by qualification, was hospitalised after he fainted soon after he ingested the chemical component.

The deceased, K.Sivanesan, 47, of Perungudi, was with Chennai-based Sujatha Biotech, an Ayurvedic and herbal products company which was founded 30 years ago. It has a plant in Kashipur, Uttarakhand, where Sivanesan was working. Sivanesan had devised formulas of various products and used to visit his managing director Dr. Rajkumar frequently in the city.

Due to the lockdown, Sivanesan came to Chennai and stayed with his family in Perungudi. On Thursday morning, he procured the chemical component from a market in Parry’s Corner.

First he gave a small amount powder he derived from the chemical to 67 years-old Rajkumar who fainted after tasting it.

Even as he was being resuscitated, Sivanesan went into the kitchen of the house and gulped it in liquid form after adding water to it. He could not be revived.

Deputy Commissioner of Police, T.Nagar, Ashok Kumar, said, “Our investigation revealed that Sivanesan died after drinking the preparation he claimed would help COVID-19 patients. His managing director fainted after tasting it initially. Further investigation is on.”

Sivanesan was rushed to a private hospital in T.Nagar and declared dead by the doctors there. Later his body was shifted to Government Royapettah Hospital for post-mortem. Teynampet police registered a case under section 174 of Criminal Procedure Code for unnatural death.

N.S.Vasan, designer-cum-media manager of the company said, “Due to the lockdown, Sivanesan stayed in the city and one day told us he heard of some medicine from U.S. President Donald Trump’s recent speech for curing Coronavirus. He said it would bring more immunity and help to prevent COVID-19. Deciding to test the effect of the medicine, he went to Parry’s Corner and bought the powder.” He added that Sivanesan must have taken a heavy dosage of the ‘drug’ and he was killed instantly.